Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy
Locally advanced basal cell carcinoma (laBCC) remains a significant management challenge. Historically, surgery or radiotherapy represented the major treatment options. Recently, hedgehog inhibitors and checkpoint inhibitors have demonstrated significant activity. The optimal sequencing of these app...
Saved in:
Main Authors: | Chalette Lambert-Swainston, Wolfram Samlowski, Brandon Reynolds, Amin Hedayat |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1500785/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report
by: Zhuren Ruan, et al.
Published: (2025-12-01) -
Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01) -
Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01) -
Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01) -
Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01)